What did the Harvard heart transplant study find?
Transplanted hearts take on the biological age of the body they are placed in. A team led by Jesse Poganik and Vadim Gladyshev at Harvard Medical School and Brigham and Women's Hospital measured the effect with DNA methylation clocks, which estimate how old a tissue is from chemical tags on its DNA, and posted the results as a bioRxiv preprint in September 2026 that has not yet been peer reviewed. The team grafted an extra heart from young, middle-aged and old mice into mice of each age, so every animal lived with its own heart and the graft. A young heart placed in an old mouse aged faster, and an old heart placed in a young mouse measured younger. By the time the grafts were examined, four to six months after surgery, each had shifted toward the recipient's biological age. The researchers then tested archived biopsies from 11 human heart transplants with large age gaps, 8 to 24 years for older hearts placed in younger recipients and 38 to 50 years for younger hearts placed in older ones, and found the same shift. Nature covered the study on 28 September 2026.
Did a young heart make the recipient younger?
A young heart did not make its recipient any younger. The mouse experiments also measured each recipient's native heart, liver and blood, and the preprint reports that the effect "was limited to the grafted tissue without reciprocal effects on systemic biological age of the recipient." The body changed the organ, and the organ did not change the body. The human data point the same way: in hundreds of recipients examined one year after transplant, heart rate, the thickness of the heart's back wall and exercise capacity tracked the recipient's age more closely than the donor's. The lead author told Nature that some, but not all, of those measures followed the prediction, and that "some things are probably simply irreversible." For the long-running question of whether young tissue can reverse aging in an older person, the result is a clear answer for the heart: the graft took on the recipient's age, and the recipient did not take on the graft's.
Do transplanted hair follicles adapt to their new site?
Transplanted hair follicles take on some traits of the site they are moved into. When Hwang and colleagues moved scalp follicles to the lower leg, the hairs grew at about half their original speed, 8.2 mm a month compared with 16.0 mm on the scalp, and 60.2% survived at three years. A second study of scalp hair moved into the eyebrows found slower growth and less graying than the hair left at the donor site. Its authors concluded that the recipient site "may have an influence on the transplanted hairs." Growth speed and graying, two traits once assumed to travel with the follicle, change with the follicle's new environment.
Resistance to DHT is the trait transplant surgery relies on. Norman Orentreich showed in 1959 that follicles taken from the back of the scalp, where hair resists the effects of DHT, keep growing after they are moved to a balding area, a principle called donor dominance. In the 2002 study, 12 patients followed for a year after occipital hair was moved to the frontal scalp showed no difference in growth rate or shaft diameter from the donor hair, and a 158-patient series found more than 85% of patients kept over 95% of their transplanted follicles at 12 months.
What is recipient dominance in hair transplants?
Recipient dominance is the case in which the site a follicle is moved into overrides the traits the follicle brought with it. The clearest example comes from scarring hair loss. In frontal fibrosing alopecia, eyebrow grafts taken from unaffected occipital scalp grew well at first, and 80% of the 10 patients had excellent growth at 6 to 12 months. Most then began losing the transplanted hairs after three to four years, and only 1 patient kept them past four years. The same environment that destroyed the original eyebrow hair destroyed the transplanted hair, the same direction of influence the heart study found: the recipient changed the graft.
Why is a hair transplant not a cure for hair loss?
A hair transplant is not a cure because it moves hair without changing the scalp the hair is moved into. The native follicles around the grafts are still exposed to DHT, and androgenetic alopecia keeps progressing in them. The finasteride trials show how steady that progression is: in the placebo arm of the pivotal study of 1,553 men, "treatment with placebo resulted in progressive hair loss." A transplant also creates no new hair. A typical first session moves around 2,000 grafts out of roughly 100,000 follicles on the scalp, and the safe donor zone is finite, so hair lost after the procedure competes for a limited supply. Hair transplant practice guidelines state that surgery "should not be considered as a single-step permanent solution for androgenetic alopecia (AGA), since the hair loss in AGA is a continuous process."
How do patients keep the rest of their hair after a transplant?
Patients keep the rest of their hair by treating the scalp the grafts sit in. Finasteride lowers the DHT that drives miniaturization, and minoxidil extends the growth phase of the follicles it reaches. In a randomized, double-blind trial of 79 men, finasteride 1 mg taken around the time of a transplant produced visible increases in the surrounding hair in 94% of men, compared with 67% on placebo. The same guidelines recommend that every patient "should be educated about the importance of continuing the medical management even after the HT surgery," and surveys of transplant surgeons report finasteride 1 mg as the treatment they most often prescribe alongside surgery. Patients who stop treatment, or never start it, often see the native hair around their grafts thin over the following years and return for a second procedure to fill the new gaps.
What the heart study does not show
The heart study is a preprint and has not been peer reviewed. Its human arm rests on 11 archived biopsies, and the authors note that fixed, paraffin-embedded samples are not ideal for DNA methylation profiling. The preprint does not report how long after transplant those biopsies were taken, so the four to six month timeline applies to mice. Epigenetic clocks estimate biological age from methylation patterns and are not a direct measure of how well an organ works, and only some of the functional measures tracked the recipient's age. The study examined hearts, not hair follicles, and its mouse model does not include the immune rejection and immunosuppressive drugs that human transplant recipients live with. The recipient dominance evidence for hair comes from small studies, and the frontal fibrosing alopecia result describes a scarring disease rather than pattern hair loss.
This article is for educational purposes and is not medical advice. Talk to a physician before starting or changing any hair loss treatment.
Frequently asked questions
Do transplanted organs take on the age of the recipient?
A September 2026 Harvard preprint found that transplanted hearts shift toward the recipient's biological age, measured with DNA methylation clocks. In mice the shift was present four to six months after surgery, and archived biopsies from 11 human heart transplants showed the same pattern. The study has not yet been peer reviewed.
Can a young organ make an older person younger?
The Harvard heart transplant preprint found no such effect. Young hearts grafted into old mice aged faster, and the recipients' own hearts, livers and blood showed no change in biological age. The influence ran from the recipient to the organ, not from the organ to the recipient.
Do transplanted hair follicles adapt to the recipient site?
Transplanted hair follicles take on some traits of their new site. Scalp hair moved to the leg grew at about half its original speed, and scalp hair moved to the eyebrows grew slower and grayed less. Hair moved from the back of the scalp to a balding area generally keeps growing, which is why transplants work in pattern hair loss.
What is recipient dominance in hair transplantation?
Recipient dominance describes cases where the site a follicle is moved into overrides the traits it brought with it. In frontal fibrosing alopecia, a scarring hair loss, eyebrow grafts from unaffected scalp grew well at first, but most patients began losing them after three to four years, and only 1 of 10 kept them past four years.
Why do people need a second hair transplant?
Androgenetic alopecia keeps progressing in the native hair that was not moved. As that hair thins, new gaps open around the original grafts, and some patients return for another procedure to fill them. Hair transplant guidelines recommend continuing medical therapy after surgery to slow that progression.
Should you take finasteride after a hair transplant?
Hair transplant guidelines recommend continuing medical therapy after surgery, and finasteride 1 mg is the treatment surgeons most often prescribe. In a randomized trial of 79 men, finasteride taken around the time of a transplant led to visible improvement in the surrounding hair in 94% of men, compared with 67% on placebo.
